GMAB
Price
$20.52
Change
-$0.22 (-1.06%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
12.79B
42 days until earnings call
LSTA
Price
$2.51
Change
+$0.11 (+4.58%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
21.67M
53 days until earnings call
Interact to see
Advertisement

GMAB vs LSTA

Header iconGMAB vs LSTA Comparison
Open Charts GMAB vs LSTABanner chart's image
Genmab A/S ADS
Price$20.52
Change-$0.22 (-1.06%)
Volume$7.58K
Capitalization12.79B
Lisata Therapeutics
Price$2.51
Change+$0.11 (+4.58%)
VolumeN/A
Capitalization21.67M
GMAB vs LSTA Comparison Chart in %
Loading...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMAB vs. LSTA commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMAB is a Buy and LSTA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (GMAB: $20.74 vs. LSTA: $2.40)
Brand notoriety: GMAB and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GMAB: 392% vs. LSTA: 20%
Market capitalization -- GMAB: $12.79B vs. LSTA: $21.67M
GMAB [@Biotechnology] is valued at $12.79B. LSTA’s [@Biotechnology] market capitalization is $21.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMAB’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 0 green FA rating(s).

  • GMAB’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 0 green, 5 red.
According to our system of comparison, both GMAB and LSTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMAB’s TA Score shows that 4 TA indicator(s) are bullish while LSTA’s TA Score has 4 bullish TA indicator(s).

  • GMAB’s TA Score: 4 bullish, 6 bearish.
  • LSTA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, LSTA is a better buy in the short-term than GMAB.

Price Growth

GMAB (@Biotechnology) experienced а -5.86% price change this week, while LSTA (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +32.23%, and the average quarterly price growth was +16.56%.

Reported Earning Dates

GMAB is expected to report earnings on Aug 07, 2025.

LSTA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($12.8B) has a higher market cap than LSTA($21.7M). GMAB YTD gains are higher at: -0.623 vs. LSTA (-19.463). GMAB has higher annual earnings (EBITDA): 1.35B vs. LSTA (-21.48M). GMAB has more cash in the bank: 3.23B vs. LSTA (25.8M). LSTA has less debt than GMAB: LSTA (92K) vs GMAB (143M). GMAB has higher revenues than LSTA: GMAB (3.12B) vs LSTA (1M).
GMABLSTAGMAB / LSTA
Capitalization12.8B21.7M58,986%
EBITDA1.35B-21.48M-6,293%
Gain YTD-0.623-19.4633%
P/E Ratio12.04N/A-
Revenue3.12B1M311,500%
Total Cash3.23B25.8M12,504%
Total Debt143M92K155,435%
FUNDAMENTALS RATINGS
GMAB vs LSTA: Fundamental Ratings
GMAB
LSTA
OUTLOOK RATING
1..100
7256
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5764
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GMAB's Valuation (50) in the null industry is in the same range as LSTA (50). This means that GMAB’s stock grew similarly to LSTA’s over the last 12 months.

GMAB's Profit vs Risk Rating (100) in the null industry is in the same range as LSTA (100). This means that GMAB’s stock grew similarly to LSTA’s over the last 12 months.

GMAB's SMR Rating (100) in the null industry is in the same range as LSTA (100). This means that GMAB’s stock grew similarly to LSTA’s over the last 12 months.

GMAB's Price Growth Rating (57) in the null industry is in the same range as LSTA (64). This means that GMAB’s stock grew similarly to LSTA’s over the last 12 months.

GMAB's P/E Growth Rating (92) in the null industry is in the same range as LSTA (100). This means that GMAB’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMABLSTA
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 16 days ago
62%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 15 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNN29.850.68
+2.33%
Smith & Nephew plc
HBNC15.200.11
+0.73%
Horizon Bancorp
BANC13.90-0.01
-0.07%
Banc of California
PIII6.03-0.14
-2.27%
P3 Health Partners Inc
SNES3.67-0.19
-4.92%
SenesTech Inc.

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+0.29%
GNMSF - GMAB
58%
Loosely correlated
N/A
AXON - GMAB
47%
Loosely correlated
+1.41%
ARVN - GMAB
38%
Loosely correlated
+4.59%
TECH - GMAB
38%
Loosely correlated
+1.42%
ARGX - GMAB
38%
Loosely correlated
+5.05%
More

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+0.42%
RAIN - LSTA
29%
Poorly correlated
N/A
GMAB - LSTA
27%
Poorly correlated
+0.29%
IMVT - LSTA
26%
Poorly correlated
+3.43%
ASND - LSTA
26%
Poorly correlated
+1.89%
MRUS - LSTA
25%
Poorly correlated
+2.64%
More